Table 3.
PDL-1 expression in cutaneous adnexal carcinomas
| n | PD-L1 tumor cells | PD-L1 immune cells | |||
|---|---|---|---|---|---|
| Positivea (%) | Negative (%) | Positiveb (%) | Negative (%) | ||
| Sweat gland carcinoma | 60 | 8 (13) | 52 (87) | 11 (18) | 49 (82) |
| Porocarcinoma | 14 | 1 (7) | 13 (93) | 3 (21) | 11 (79) |
| Hidradenocarcinoma | 11 | 1 (9) | 10 (91) | 2 (18) | 9 (82) |
| Ductal adenocarcinoma NOS | 10 | 0 (0) | 10 (100) | 1 (10) | 9 (90) |
| Microcystic adnexal carcinoma | 5 | 0 (0) | 5 (100) | 0 (0) | 5 (100) |
| Syringoid eccrine carcinoma | 5 | 0 (0) | 5 (100) | 0 (0) | 5 (100) |
| Apocrine carcinoma | 5 | 2 (40) | 3 (60) | 1 (20) | 4 (86) |
| Invasive EMPD | 7 | 4 (57) | 3 (43) | 4 (57) | 1 (43) |
| Digital papillary adenocarcinoma | 2 | 0 (0) | 2 (100) | 0 (0) | 2 (100) |
| Adenoid cystic carcinoma | 1 | 0 (0) | 1 (100) | 0 (0) | 1 (100) |
| Sebaceous carcinoma | 18 | 1 (6) | 17 (94) | 5 (28) | 13 (72) |
| Trichoblastic carcinoma | 5 | 0 (0) | 5 (100) | 4 (80) | 1 (20) |
| Total | 83 | 9 (11) | 74 (89) | 20 (24) | 63 (76) |
NOS no other specification, EMPD extramammary Paget disease
aPD-L1 is considered positive (+) applying a cut-off of ≥ 1% of tumor cells (TC1–3)
bPD-L1 is considered positive (+) applying a cut-off of ≥ 1% of immune cells (IC1–3)